Compare ADMA Biologics Inc (ADMA) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs VanEck Gold Miners ETF — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while VanEck Gold Miners ETF trades at $73.27. The key difference: VanEck Gold Miners ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | GDX | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $115.84 |
52-Week Low | $7.60 | $50.79 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
GDX trades at $78.74, up 0.4% with bearish technical signals from moving averages but neutral oscillators. The ETF faces mixed sentiment as gold miners navigate volatile commodity markets, though some analysts highlight attractive valuations and strong fundamentals. Recent additions like Aya Gold & Silver to the ETF portfolio signal ongoing portfolio optimization.
The outlook remains cautious with technical resistance at $80-$83, while fundamental support comes from record free cash flow yields and discounted multiples. Key risks include gold price volatility and energy cost pressures, but central bank demand and portfolio diversification benefits provide long-term tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
